ConductScience.org, home

Paper · 36498473

References96

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133,292,582The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome.J Intensive Care2020https://conductscience.org/library/papers/33292582PubMed
210,990,106Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score.Intensive Care Med2000https://conductscience.org/library/papers/10990106PubMed
321,333,028Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients.BMC Anesthesiol2011https://conductscience.org/library/papers/21333028PubMed
419,397,464Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.Pharmacotherapy2009https://conductscience.org/library/papers/19397464PubMed
523,642,005Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?Crit Care2013https://conductscience.org/library/papers/23642005PubMed
627,451,086Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.Int J Antimicrob Agents2016https://conductscience.org/library/papers/27451086PubMed
730,626,244Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.Expert Opin Drug Metab Toxicol2019https://conductscience.org/library/papers/30626244PubMed
828,571,493Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?Expert Rev Anti Infect Ther2017https://conductscience.org/library/papers/28571493PubMed
931,358,583Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.Antimicrob Agents Chemother2019https://conductscience.org/library/papers/31358583PubMed
1024,768,475Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Lancet Infect Dis2014https://conductscience.org/library/papers/24768475PubMed
1128,158,470Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.J Antimicrob Chemother2017https://conductscience.org/library/papers/28158470PubMed
1216,355,321The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs.Clin Infect Dis2006https://conductscience.org/library/papers/16355321PubMed
1334,224,115Pharmacokinetics of Commonly Used Antimicrobials in Critically Ill Adults During Extracorporeal Membrane Oxygenation: A Systematic Review.Drugs2021https://conductscience.org/library/papers/34224115PubMed
1431,325,141What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.Clin Pharmacokinet2019https://conductscience.org/library/papers/31325141PubMed
1534,034,594Oxygenator impact on meropenem/vaborbactam in extracorporeal membrane oxygenation circuits.Perfusion2022https://conductscience.org/library/papers/34034594PubMed
1627,012,450Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy.Pharmacotherapy2016https://conductscience.org/library/papers/27012450PubMed
1715,656,698Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.Clin Pharmacokinet2005https://conductscience.org/library/papers/15656698PubMed
1834,250,190Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration.Open Forum Infect Dis2021https://conductscience.org/library/papers/34250190PubMed
1920,862,453Determinants of drug absorption in different ECMO circuits.Intensive Care Med2010https://conductscience.org/library/papers/20862453PubMed
2023,683,557Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy.J Crit Care2013https://conductscience.org/library/papers/23683557PubMed

papers-2026-11-12-0.1.0

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/36498473/references